BofA Securities resumed coverage on Regeneron Pharma with a new price target
$REGN
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities resumed coverage of Regeneron Pharma with a rating of Underperform and set a new price target of $565.00